174
Participants
Start Date
December 18, 2013
Primary Completion Date
December 12, 2023
Study Completion Date
December 12, 2023
CC-122
2mg or 3 mg administered orally once daily
CC-223
20mg or 30mg administered orally once daily.
Rituximab
375 mg/m2 administered intravenously once every 28 days
CC-122
2mg or 3mg administered orally once daily.
CC-292
500 mg twice a day administered orally.
Rituximab
375 mg/m2 administered intravenously once every 28 days
CC-223
20mg or 30mg per day administered orally daily.
CC-292
500 mg twice a day administered orally.
Rituximab
375 mg/m2 administered intravenously once every 28 days
Local Institution - 201, Turin
Local Institution - 200, Rozzano (MI)
Local Institution - 202, Milan
Local Institution - 102, Bordeaux
Local Institution - 005, Tampa
Local Institution - 001, Nashville
Local Institution - 007, Madison
Mayo Clinic, Rochester
Northwestern University, Chicago
Local Institution - 101, Lyon
Stanford Cancer Center, Stanford
Local Institution - 100, Villejuif
Yale Cancer Center, New Haven
MD Anderson Cancer Center, Houston
Local Institution - 402, Edmonton
Local Institution - 400, Toronto
Lead Sponsor
Celgene
INDUSTRY